Eric Meier brings over 25 years of experience in the development of innovative software, medical devices, and drug delivery solutions. He is currently President and CEO of Owl. Prior to Owl, Eric served as CEO of Cervel Neurotech, a non-invasive deep brain stimulation offering for the treatment of psychiatric and neurological disorders, until its sale to Rio Grande Neuroscience. Previously, he was Founder and CEO of Calypso Medical, a platform for the delivery of targeted external beam radiation treatment, which was acquired by Varian Medical Systems. Eric also led a variety of corporate development activities at Johnson & Johnson. Eric received his MBA from Stanford University.
There will be more pilots and programs of value-based reimbursement contracts between payers and providers. The traditional fee-for-service model won’t disappear for years to come, but there will be thoughtful pilots of reimbursement programs that reward providers for quality of care and clinical outcomes.
Expanding access to care and improving clinical outcomes are the critical priorities in overcoming the behavioral health crises that we are all now facing. It’s the data from measurement-based care solutions that will get us where we need to be, on a pathway to break through this crisis once and for all...with confidence.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
To prepare for this next wave, healthcare systems and community mental health organizations must find ways to scale resources to efficiently screen patients for behavioral health conditions, match them with the right resources and then monitor their progress over time